Preview Mode Links will not work in preview mode

MedEdTalks - Oncology

May 11, 2021

Within this podcast, Improving Provider Confidence in Patient Identification and the Administration of Oncolytic Viral Therapy, Dr. Howard Kaufman and Dr. Anna C. Pavlick examine the patient and tumor characteristics that may make a patient with advanced melanoma a good candidate for oncolytic viral therapy with...


May 11, 2021

Within this podcast, Mechanisms of Oncolytic Viral Therapy, Dr. Howard Kaufman and Professor Kevin Harrington review the rationale for the use of oncolytic viral therapies as monotherapy or in combination with checkpoint inhibitors for patients with advanced melanoma.


May 11, 2021

Within this podcast, Overview of Oncolytic Viral Therapy – Focus on Melanoma, Dr. Howard Kaufman and Dr. Dmitriy Zamarin evaluate the latest advances regarding the use of oncolytic viral therapy for cancer management, particularly in the context of advanced melanoma. 


May 10, 2021

Within the podcast, Oncolytic Viral Therapy – A Look at the Latest Evidence, Dr. Howard Kaufman and Dr. Ann Silk assess the latest clinical evidence regarding available and emerging oncolytic viral therapies for the management of patients with advanced melanoma.


Nov 11, 2019

Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. Theses rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted...